NovaBay Pharmaceuticals, Inc. Ownership and Conversion Details

On October 9, 2025, R01 Fund LP purchased all of David Lazar's rights, title, and interest in 220,663 shares of NovaBay Pharmaceuticals, Inc.'s Series D Non-Voting Convertible Preferred Stock and the rights to purchase 134,375 shares of Series E Non-Voting Convertible Preferred Stock. Following stockholder approval at the annual meeting on October 16, 2025, each share of Series D Preferred Stock will automatically convert into 160 shares of common stock, and the Series E Preferred Stock will be issued, with each share converting into 160 shares of common stock. The reported securities may also be deemed beneficially owned by R01 Capital LLC, R01 Capital Manager LLC, and Michael Kazley, who disclaim beneficial ownership except to the extent of their pecuniary interest. Michael Kazley, the Chief Executive Officer and a director of NovaBay Pharmaceuticals, Inc., is a ten percent owner.